Randomized trial: Lopinavir–ritonavir not beneficial for patients admitted to hospital with COVID-19

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet

Commentaries: Study: HIV drug of no benefit to hospitalized COVID patients – CIDRAP AND Antiviral monotherapy for hospitalised patients with COVID-19 is not enough – The Lancet AND

Commentary on Twitter

NEW—Lopinavir-ritonavir is not an effective treatment for patients hospitalised with #COVID19: finding from RECOVERY, randomised, controlled, open-label, platform trial https://t.co/RpiUAvWF1I pic.twitter.com/uI3yiQbEgK

— The Lancet (@TheLancet) October 6, 2020